4.11
+0.1(+2.49%)
Currency In USD
| Previous Close | 4.01 |
| Open | 3.98 |
| Day High | 4.17 |
| Day Low | 3.9 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.92 |
| Volume | 45,522 |
| Average Volume | 78,223 |
| Market Cap | 38.03M |
| PE | -1.38 |
| EPS | -2.97 |
| Moving Average 50 Days | 5.93 |
| Moving Average 200 Days | 7.6 |
| Change | 0.1 |
If you invested $1000 in CervoMed Inc. (CRVO) 10 years ago, it would be worth $0.04 as of March 09, 2026 at a share price of $4.11. Whereas If you bought $1000 worth of CervoMed Inc. (CRVO) shares 5 years ago, it would be worth $57.68 as of March 09, 2026 at a share price of $4.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
GlobeNewswire Inc.
Mar 04, 2026 12:30 PM GMT
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps w
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
GlobeNewswire Inc.
Feb 18, 2026 11:00 AM GMT
Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK-based trial first to evaluate neflamapimod in ALS
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
GlobeNewswire Inc.
Dec 04, 2025 10:00 PM GMT
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggestin